Sonnet BioTherapeutics Pivots Into Crypto With $888M Hyperliquid Treasury Strategy
Nasdaq-listed biotech firm Sonnet BioTherapeutics is making a bold move into the digital asset space, unveiling plans to launch an $888 million Hyperliquid (HYPE) token treasury under a newly formed entity.
Nasdaq-listed biotech firm Sonnet BioTherapeutics is making a bold move into the digital asset space, unveiling plans to launch an $888 million Hyperliquid (HYPE) token treasury under a newly formed entity.
On Monday, Sonnet announced it had entered into a business combination with Rorschach, a company it recently created, to spearhead its new crypto-focused strategy. This move will see Sonnet transform into Hyperliquid Strategies Inc. (HSI), positioning it as the largest publicly traded U.S. company to hold HYPE tokens on its balance sheet.
HSI intends to acquire 12.6 million HYPE tokens, worth approximately $583 million at the time of the agreement. Alongside this, it will hold $305 million in cash reserves, bringing the total value of the entity to $888 million. The company also hinted that part of its cash reserves will be used to purchase additional HYPE tokens going forward.
Hyperliquid, the token at the centre of this pivot, powers a high-throughput layer-1 blockchain designed for onchain trading of perpetual futures and other advanced financial instruments. According to CoinGecko, Hyperliquid currently ranks as the 12th-largest token globally, boasting a market capitalization of $16.2 billion.
Source:
CoinGhecko
By creating HSI, Sonnet offers traditional equity investors indirect exposure to HYPE, bridging the gap between conventional finance and emerging blockchain technologies. This strategy mirrors the approach of Strategy, the business intelligence firm that famously pivoted into Bitcoin investments, giving stock market investors exposure to crypto without direct token purchases.
The initiative is backed by heavyweight institutional investors including Atlas Merchant Capital, Paradigm, Galaxy Digital, Pantera Capital, D1 Capital, Republic Digital, and 683 Capital. Paradigm co-founder Matt Huang described Hyperliquid as a crypto project with robust fundamentals, noting growing institutional appetite for HYPE exposure despite its limited accessibility in the U.S.
Similarly, Eyenovia, Inc., a Nasdaq-listed ophthalmic technology company, announced a significant $50 million investment in Hyperliquid’s native cryptocurrency, HYPE.
While Sonnet undergoes this significant transformation, it will continue operating its clinical oncology portfolio under HSI’s corporate umbrella.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
As AI controversies escalate, hedge funds buy tech stocks at the fastest pace in 15 months
Hedge funds have recorded net purchases of US TMT stocks on 10 out of the past 11 trading days, rebuilding tech long positions at the fastest pace in 15 months. However, an AI policy storm has struck at the "worst possible time"—calls by AI giants to slow down development have been rejected, and regulatory uncertainty has directly hit Asian tech stocks such as Softbank. As the tech sector's bullish run coincides with Super Central Bank Week, the sector now faces a severe test.
Apple Pre-sale Tracker: iPhone 18 Pro Series Shows Weak Overseas Demand Signals, Duo Review Positive but Hardware Lags Behind
According to a survey by Jefferies, after the launch of the iPhone 18 Pro, delivery wait times in the four major markets—the US, UK, Germany, and Japan—have shortened by 5 to 11 days compared to last year, with no wait time in the US. Given stable production capacity, this is a clear sign of weak demand. Although the China and Hong Kong markets have performed better against the trend, there are still suspicions of speculative stockpiling. The new foldable Duo has been praised for its software experience, but its $2,000 price tag comes with a 254-gram body and dual-camera setup, leaving its hardware lagging significantly behind Android competitors. Jefferies maintains an "underperform" rating, with a target price implying a 21% downside from the current level.
SUI holds $0.71 support as analysts cite key buy signal, eyes on possible recovery
UBS Health Benefit Survey: Elevance Health (ELV.US) Leads, U.S. Employers Prepare for Rising Medical Costs
In the annual survey by UBS for employee benefits management institutions, Elevance Health (ELV.US) emerged as the highest-rated US health insurance company.
Crypto prices
More
